The FDA has approved AstraZeneca’s SGLT2 inhibitor Farxiga as a treatment candidate for all patients with heart failure, putting the drug back in contention with rival Jardiance from Boehringer ...

AstraZeneca's Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patients ...

Farxiga (dapagliflozin) and Jardiance (empagliflozin) are prescription medications that are commonly used for type 2 diabetes ...

Diabetes and heart health are closely connected. People with diabetes have a higher risk of heart failure, a condition where ...